【Abstract】 Objective To investigate the clinical effect of compound anisodine combined with adenosine Cobalt on the treatment of patients with ischemic optic neuropathy. Methods 76 eyes of 52 patients with ischemic optic neuropathy who accepted therapy in our hospital from May 2015 to May 2016 were randomly divided into control group and experimental group. The patients in control group were given compound anisodine to the eyes. The patients in experimental group were given compound anisodine plus adenosin cobalt amine to the eyes. The total effective rate, visual acuity distribution, visual acuity, visual field defect, the corresponding blood vessel parameters and color arterial blood flow were compared between the two groups. Results The total effective rate of the experimental group was significantly higher than that of the control group, and the distribution of visual acuity after treatment was significantly better than that of the control group (P <005). The level of visual field defect in the visual acuity group was significantly lower than that in the control group (P<005). After treatment, the levels of PSV, EDV and TAMX in CRA, OA and SPCA were significantly higher than those in control group (P <001). The blood flow velocities of CRA, OA and SPCA were improved in both groups after treatment, and the improvement extent of the experimental group was more significant (P<005).Conclusion The comprehensive intervention effect of compound anisodine plus adenosine Cobalt amine in the treatment of ischemic optic neuropathy is significant.